RGRX REGENERX BIOPHARMACEUTICALS
This stock just completed a major bottoming pattern and buy volume just started.
This is not for investors but rolling the dice on this stock could double in a few days.
RGRX REGENERX BIOPHARMACEUTICALS is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands.
The news is there partner has just be bought out much larger entity HLB Consortium. With that news the possibility of acquisition by HLB Consortium also.
This is not for investors but rolling the dice on this stock could double in a few days.
RGRX REGENERX BIOPHARMACEUTICALS is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands.
The news is there partner has just be bought out much larger entity HLB Consortium. With that news the possibility of acquisition by HLB Consortium also.
Komen:
AS we strengthen I am looking for a break out of the very long base that would take us through .315 area and with that .60 and w e will challenge the highs. As chartist we must assume that news is driving the buying so my target has been raised to $3.00
Dagangan ditutup: sasaran tercapai